Celsius Holdings, Inc. Common Stock
CELH
$31.29
+1.86%
Celsius Holdings, Inc. is a consumer defensive company operating in the non-alcoholic beverage industry, specifically the energy drink subsegment, with 95% of its revenue concentrated in North America. It owns three energy drink brands—Celsius, Alani Nu, and Rockstar Energy—and leverages a capital-light model by outsourcing manufacturing and distribution to third parties, including a strategic partnership with PepsiCo, which holds an 11% stake. The company has transformed into a multi-brand growth platform following the acquisition of Alani Nu, which helped offset slowing growth in its flagship Celsius brand. However, recent news highlights a Q2 miss and declining flagship sales, raising concerns about growth sustainability despite the stock's low valuation, while analysts remain cautiously optimistic with a Buy consensus.…
CELH
Celsius Holdings, Inc. Common Stock
$31.29
Related headlines
Investment Opinion: Should I buy CELH Today?
Rating: Hold. The stock is a speculative growth play with a consensus Buy rating and an average target of $42.05, implying 27.5% upside. However, the recent Q2 miss and declining flagship sales warrant caution. The thesis is that the Alani Nu acquisition will drive growth, but execution risks are high.
Sign up to view all
CELH 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The stock offers potential upside if growth continues, but the high trailing valuation and recent Q2 miss create significant downside risk. The key factor is whether the company can sustain growth and improve margins. If revenue growth accelerates and margins expand, the stance would upgrade to bullish. Conversely, if growth decelerates or margins compress, it would downgrade to bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celsius Holdings, Inc. Common Stock's 12-month outlook, with a consensus price target around $42.29 and implied upside of +35.1% versus the current price.
Average Target
$42.29
0 analysts
Implied Upside
+35.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$26 - $64
Analyst target range
Analyst coverage is substantial with 21 analysts, and the consensus recommendation is 'Buy' with a mean rating of 1.71 (where 1 is Strong Buy and 5 is Sell). The average target price is $42.05, implying a 27.5% upside from the current price of $32.98. The distribution is bullish, with no Sell ratings and a majority of Buy/Overweight actions from firms like Citigroup, Needham, and Morgan Stanley, indicating strong institutional conviction. The target range spans from a low of $26.00 to a high of $64.00, with the high target assuming successful execution of growth strategies and margin expansion, while the low target reflects risks of continued market share loss and competitive pressures. The wide spread of $38 suggests high uncertainty about the company's future, but recent ratings have been consistently positive, with no downgrades in the past three months, signaling that analysts see the current pullback as a buying opportunity.
Drowning in data?
Find the real signal!
Bulls vs Bears: CELH Investment Factors
Celsius presents a classic high-growth, high-risk investment. The bull case rests on the transformative Alani Nu acquisition, strong profitability, and a low forward PE, while the bear case highlights declining flagship sales, extreme trailing valuation, and earnings volatility. Currently, the bearish evidence is stronger due to the recent Q2 miss and decelerating growth, but the low forward PE and analyst optimism provide a floor. The central tension is whether the Alani Nu integration can sustain growth and justify the premium valuation, or if the core brand's decline will drag overall performance. The stock's future hinges on the next few quarters' ability to show consistent revenue and earnings growth.
Bullish
- Massive Revenue Growth from Alani Nu: Q1 2026 revenue surged 137.7% YoY to $782.6M, driven by the Alani Nu acquisition, transforming Celsius into a multi-brand platform. This diversification reduces reliance on the flagship Celsius brand and expands market reach.
- Strong Profitability and Margins: Q1 2026 net income of $110.1M (14.1% net margin) and gross margin of 48.3% demonstrate robust profitability. The company generated $292.8M in TTM free cash flow, supporting growth investments and financial flexibility.
- Analyst Consensus Buy with Upside: 21 analysts rate CELH a Buy (mean 1.71), with an average target of $42.05, implying 27.5% upside. No Sell ratings and recent positive actions from Citigroup, Needham, and Morgan Stanley signal institutional confidence.
- Low Forward Valuation: Forward PE of 18.89x is at a 14% discount to the industry average of 22x, suggesting the market is pricing in substantial earnings growth. If EPS reaches $2.10 as estimated, the stock appears reasonably valued.
Bearish
- Declining Flagship Brand Sales: Recent Q2 miss and declining Celsius brand sales raise concerns about core brand momentum. The 1-year price decline of -44.75% reflects investor worry that growth is slowing despite the Alani Nu boost.
- Extremely High Trailing PE: Trailing PE of 182.96x is 731% above the industry average of 22x, indicating the market is paying a premium for past earnings. This leaves little room for error and makes the stock vulnerable to multiple compression.
- Revenue Growth Deceleration: Sequential revenue plateaued: Q3 2025 $725.1M, Q4 2025 $721.6M, Q1 2026 $782.6M (only 8.5% QoQ growth). This suggests the Alani Nu acquisition may not be delivering sustained momentum, and organic growth is slowing.
- Earnings Volatility and Losses: Net income swung from a -$61.0M loss in Q3 2025 to a $110.1M profit in Q1 2026, highlighting instability. Such volatility makes forecasting difficult and increases risk for investors.
CELH Technical Analysis
CELH is in a pronounced downtrend over the past year, with a 1-year price change of -44.75%, significantly underperforming the S&P 500's +18.56% gain. The current price of $32.98 sits at 22.6% of its 52-week range (between $23.56 low and $66.74 high), indicating the stock is trading near the lower end of its yearly range. This positioning suggests a potential value opportunity, but also reflects persistent selling pressure and a lack of investor conviction, as the stock has failed to recover meaningfully from its lows.
Beta
0.92
0.92x market volatility
Max Drawdown
-63.4%
Largest decline past year
52-Week Range
$24-$67
Price range past year
Annual Return
-49.0%
Cumulative gain past year
| Period | CELH Return | S&P 500 |
|---|---|---|
| 1m | +10.8% | +1.0% |
| 3m | +12.8% | +1.1% |
| 6m | -27.1% | +13.8% |
| 1y | -49.0% | +19.5% |
| ytd | -34.5% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CELH Fundamental Analysis
Revenue growth has been robust but decelerating, with the most recent quarter (Q1 2026) reporting revenue of $782.6 million, a 137.7% YoY increase from $329.3 million in Q1 2025, driven largely by the Alani Nu acquisition. However, sequential growth has slowed, with Q4 2025 revenue of $721.6 million and Q3 2025 revenue of $725.1 million, indicating a plateau. The company's net income of $110.1 million in Q1 2026, with a net margin of 14.1%, shows strong profitability, but this is a sharp recovery from a loss of $61.0 million in Q3 2025, highlighting volatility. Gross margin remains healthy at 48.3% in Q1 2026, though slightly down from 51.5% in Q2 2025, reflecting competitive pressures and mix shifts.
Quarterly Revenue
$782615000.0B
2026-03
Revenue YoY Growth
+137.7%
YoY Comparison
Gross Margin
48.3%
Latest Quarter
Free Cash Flow
$292759000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CELH Overvalued?
Given positive net income, the PE ratio is the primary valuation metric. The trailing PE of 182.96x is extremely elevated, while the forward PE of 18.89x implies a dramatic earnings growth expectation, with analysts estimating EPS of $2.10 for the next fiscal year. This gap suggests the market expects a massive earnings surge, likely from the Alani Nu integration and cost synergies, but also leaves little room for error. Compared to the industry average PE of 22x (from valuation data), CELH trades at a 731% premium on trailing earnings, but a 14% discount on forward earnings, indicating the market is pricing in above-average growth. Historically, the stock's PE has ranged from -47x to 285x over the past two years, with the current trailing PE near the higher end, suggesting the market is pricing in optimistic expectations that may already be reflected in the price.
PE
183.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 27x~153x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
54.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant. The company's trailing PE of 182.96x is extremely elevated, implying the market expects massive future earnings growth. If growth disappoints, the stock could face severe multiple compression. Additionally, net income has been volatile, swinging from a -$61.0M loss in Q3 2025 to a $110.1M profit in Q1 2026, indicating unstable profitability. The debt-to-equity ratio of 0.23 is manageable, but the company's reliance on the Alani Nu acquisition for growth creates integration risk. Free cash flow of $292.8M TTM is positive, but the high payout ratio of 34.8% (though no dividend is paid) suggests capital allocation may be suboptimal.
